Current pharmacological treatments for nicotine dependence

Trends in Pharmacological Sciences

Volumn 25, Issue 1, 2004, Pages 42-48

  George, Tony P ^a   O'Malley, Stephanie S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BUSPIRONE; CANNABINOID; CLONIDINE; DOPAMINE; DOXEPIN; DRUGS USED IN THE TREATMENT OF ADDICTION; FLUOXETINE; GLUTAMIC ACID; MECAMYLAMINE; MOCLOBEMIDE; NALTREXONE; NEUROTRANSMITTER; NICOTINE; NICOTINE GUM; NICOTINE LOZENGE; NICOTINE NASAL SPRAY; NICOTINE PATCH; NICOTINE VAPOR; NORADRENALIN; NORTRIPTYLINE; OPIATE; PLACEBO; SELEGILINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANXIETY; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL TRIAL; DEATH; DESENSITIZATION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; DYSPHORIA; EPIDEMIOLOGICAL DATA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MOOD; NERVOUSNESS; NEUROBIOLOGY; NEUROTRANSMISSION; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOPHARMACOLOGY; RELAPSE; REVIEW; SEIZURE; SIDE EFFECT; SMOKING CESSATION; SUSTAINED RELEASE PREPARATION; TOBACCO; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 0347126799     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2003.11.003     Document Type: Review

References (74)

1. Cigarette smoking among adults in the United States, 2002. Morbidity and Mortality World Report. 51:2002;300-303.
2. Giovino G.A. Epidemiology of tobacco use in the United States. Oncogene. 21:2002;7326-7340.
3. Irvin J.E., et al. The increasing recalcitrance of smokers in clinical trials II: pharmacotherapy trials. Nicotine Tob. Res. 5:2003;27-35.
4. Hughes J.R. The future of smoking cessation therapy in the United States. Addiction. 91:1996;1797-1802.
5. Gritz E.R., et al. Smoking cessation and gender: the influence of physiological, psychological and behavioral factors. J. Am. Med. Womens Assoc. 51:1996;35-42.
6. Perkins K.A., et al. Sex-differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob. Res. 1:1999;301-315.
7. Dani J.A., De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol. Biochem. Behav. 70:2001;439-446.
8. Picciotto M.R. Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol. Sci. 23:2003;494-499.
9. Picciotto M.R., et al. Nicotinic receptors in the brain: Links between molecular biology and behavior. Neuropsychopharmacology. 22:2000;451-465.
10. Wooltorton J.R.A., et al. Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. J. Neurosci. 23:2003;3176-3185.
11. Leonard S., Bertrand D. Neuronal nicotinic receptors: from structure to function. Nicotine Tob. Res. 3:2001;203-223.
12. Zoli M., et al. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J. Neurosci. 22:2002;8785-8789.
13. Mansvelder H.D., McGehee D.S. Cellular and synaptic mechanisms of nicotine addiction. J. Neurobiol. 53:2002;606-617.
14. Marshall D.L., et al. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated animals. J. Neurochem. 68:1997;1511-1519.
15. Fowler J.S., et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 379:1996;733-736.
16. Fowler J.S., et al. Brain monoamine oxidase A: inhibition by cigarette smoke. Proc. Natl. Acad. Sci. U. S. A. 93:1996;14065-14069.
17. Rigotti N.A. Treatment of tobacco use and dependence. New Engl. J. Med. 346:2002;506-512.
18. First, M.B. (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th Edn, American Psychiatric Association, Washington.
19. Heatherton T.F., et al. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br. J. Addict. 86:1991;1119-1127.
20. Hughes J.R., et al. Measurement of abstinence in clinical trials: issues and recommendations. Nicotine Tob. Res. 5:2003;13-25.
21. Shiffman S., et al. Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacology (Berl.). 166:2003;343-350.
22. Cousins M.S., et al. Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking. Nicotine Tob. Res. 3:2001;123-129.
23. Anderson J.E., et al. Treating tobacco use and dependence: An evidence-based clinical practice guideline for tobacco cessation. Chest. 121:2002;932-941.
24. Fiore M.C. The agency for health care policy and research smoking cessation clinical practice guidelines. J. Am. Med. Assoc. 275:1996;1270-1280.
25. Hughes J.R., et al. Recent advances in the pharmacotherapy of smoking. J. Am. Med. Assoc. 281:1999;72-76.
26. Fiore M.C., et al. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. J. Am. Med. Assoc. 271:1994;1940-1947.
27. Ascher J.A., et al. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry. 56:1995;395-401.
28. Slemmer J.E., et al. Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. 295:2000;321-327.
29. Hurt R.D., et al. A comparison of sustained-release bupropion and placebo for smoking cessation. New Engl. J. Med. 337:1997;1195-1202.
30. Hays J.T., et al. Sustained-release bupropion for pharmacologic relapse-prevention after smoking cessation: a randomized, controlled trial. Ann. Intern. Med. 135:2001;423-433.
31. Sweet M. GlaxoSmithKline takes legal action to block new controls on its smoking cessation drug. Br. Med. J. 326:2003;952.
32. Bohadana A.N.F., et al. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch. Intern. Med. 160:2000;3128-3134.
33. Jorenby D.E., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New Engl. J. Med. 340:1999;685-691.
34. Rose J.E., et al. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacol. Ther. 56:1994;86-99.
35. Rose J.E., et al. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp. Clin. Psychopharmacol. 6:1998;331-343.
36. Wong G.Y., et al. A randomized trial of naltrexone for smoking cessation. Addiction. 94:1999;1227-1237.
37. Krishnan-Sarin, S. et al. Nicotine patch and naltrexone for smoking cessation: a preliminary study. Nicotine Tob. Res. (in press).
38. Prochazka A.V., et al. A randomized trial of nortriptyline for smoking cessation. Arch. Intern. Med. 158:1998;2035-2039.
39. Hall S.M., et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch. Gen. Psychiatry. 55:1998;683-690.
40. Hall S.M., et al. Psychological intervention and antidepressant treatment in smoking cessation. Arch. Gen. Psychiatry. 59:2002;930-936.
41. Edwards N.B., et al. Doxepin as an adjunct to smoking cessation: a double-blind pilot study. Am. J. Psychiatry. 146:1989;373-376.
42. Berlin I., et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin. Pharmacol. Ther. 58:1995;444-452.
43. George T.P., et al. A preliminary trial of selegiline hydrochloride versus placebo for smoking cessation. Biol. Psychiatry. 53:2003;136-143.
44. Picciotto M.R., et al. Nicotinic receptors in the brain: Links between molecular biology and behavior. Neuropsychopharmacology. 22:2000;451-465.
45. Niaura R., et al. Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. J. Consult. Clin. Psychol. 70:2002;887-896.
46. Killen J.D., et al. Nicotine patch and paroxetine for smoking cessation. J. Consult. Clin. Psychol. 68:2000;883-889.
47. Blondal T.G., et al. The effects of fluoxetine combined with nicotine inhalers in smoking cessation. Addiction. 94:1999;1007-1015.
48. Hitsman B., et al. Antidepressant pharmacotherapy helps some cigarette smokers more than others. J. Consult. Clin. Psychol. 67:1999;547-554.
49. Schneider N.G., et al. Efficacy of buspirone in smoking cessation: a placebo-controlled trial. Clin. Pharmacol. Ther. 60:1996;568-575.
50. Covey L.S., Glassman A.H. A meta-analysis of double-blind placebo-controlled trials of clonidine for smoking cessation. Br. J. Addict. 86:1991;991-998.
51. Gourlay S.G., Benowitz N. Is clonidine an effective smoking cessation therapy? Drugs. 50:1995;197-207.
52. Niaura R., et al. Transdermal clonidine for smoking cessation: a double-blind randomized dose-response study. Exp. Clin. Psychopharmacol. 4:1996;285-291.
53. Nana A.P. Clonidine for smoking cessation. J. Med. Assoc. Thai. 81:1998;87-93.
54. Pomerleau O.F. Endogenous opioids and smoking: A review of progress and problems. Psychoneuroendocrinology. 23:1998;115-130.
55. Krishnan-Sarin S., et al. Naloxone challenge in smokers: Evidence for an opioid component in nicotine dependence. Arch. Gen. Psychiatry. 56:1999;663-668.
56. Sutherland G., et al. Naltrexone, smoking behavior and cigarette withdrawal. Psychopharmacology (Berl.). 120:1995;418-425.
57. Fryer J.D., Lukas R.J. Noncompetitive functional inhibition at diverse, human nicotinic receptor subtypes by bupropion, phencyclidine, and ibogaine. J. Pharmacol. Exp. Ther. 288:1999;88-92.
58. Clarke P.B.S. Nicotinic receptor blockade therapy and smoking cessation. Br. J. Addict. 86:1991;501-505.
59. Stolerman I.P., et al. Influencing cigarette smoking with nicotinic antagonists. Psychopharmacologia. 28:1973;247-259.
60. Collins A.C., et al. Sensitivity to nicotine and brain nicotinic receptors are altered by chronic nicotine and mecamylamine infusion. J. Pharmacol. Exp. Ther. 271:1994;125-133.
61. McGehee D.S., et al. Nicotinic enhancment of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science. 269:1995;1692-1696.
62. Cousins M.S., et al. Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking. Nicotine Tob. Res. 3:2001;123-129.
63. Rimonabant SR 141716, SR 141716a. Drugs R D. 3:2002;65-66.
64. Paterson N.E., et al. The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl.). 167:2003;257-264.
65. Rasmussen K., et al. The novel 5-hydroxytryptamine 1A antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine. J. Pharmacol. Exp. Ther. 294:2000;688-700.
66. Andreoli M., et al. Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology. 28:2003;1272-1280.
67. Decker M.W., et al. The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control (review). Expert Opin. Investig. Drugs. 10:2001;1819-1830.
68. Fattore L., et al. Baclofen antagonizes intravenous self-administration of nicotine in mice and rats. Alcohol Alcohol. 37:2002;495-498.
69. Malin D.H., et al. Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol. Biochem. Behav. 68:2001;87-92.
70. Kendler K.S., et al. Smoking and major depression: a causal analysis. Arch. Gen. Psychiatry. 50:1993;36-43.
71. Hall S.M., et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch. Gen. Psychiatry. 55:1998;683-690.
72. George T.P., et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am. J. Psychiatry. 157:2000;1835-1842.
73. Rosenhow D.J., et al. Naltrexone treatment for alcoholics: Effects on cigarette smoking rates. Nicotine Tob. Res. 5:2003;231-236.
74. Lerman C., et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics. 12:2002;627-634.